Pancreatic amyloidosis study tool

733-P: Efficacy of a Novel Oral Amylin Analog and the Development of an Oral GLP-1/Amylin Coformulated Tablet to Produce High In Vivo Plasma Exposures

Article Navigation

P: Clinical Therapeutics—Incretin-Based Therapies|June 20 2025

Authors

• HAIXIA ZOU
• XINLE WU
• WANJUN GUO
• JIANHUI DENG
• CATHERINE L. JONES
• SUSAN TRIEU
• RICHARD HO
• MOHAMED EID
• JANE HUGHES
• WEIDONG ZHONG
• MARTIJN FENAUX

All authors are from Beijing, China, London, United Kingdom.

Publication Details

Diabetes 2025;74(Supplement_1):733-P

https://www.frankenthalerfoundation.org

Citation

HAIXIA ZOU, XINLE WU, WANJUN GUO, JIANHUI DENG, CATHERINE L. JONES, SUSAN TRIEU, RICHARD HO, MOHAMED EID, JANE HUGHES, WEIDONG ZHONG, MARTIJN FENAUX; 733-P: Efficacy of a Novel Oral Amylin Analog and the Development of an Oral GLP-1/Amylin Coformulated Tablet to Produce High In Vivo Plasma Exposures. Diabetes 20 June 2025; 74 (Supplement_1): 733–P. https://www.frankenthalerfoundation.org